Gå direkt till huvudinnehållet

P/S-Lipoprotein(a)

Senast reviderad:
Sakkunnig:


  1. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9. Journal of the American Medical Association  
  2. Mach F, Baigent C, Catapano CL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111-188. pmid:31591002 PubMed  
  3. Theodorsson E, Berggren Söderlund M, (red). Laurells Klinisk kemi i praktisk medicin. Lund: Studentlitteratur, 2018
  4. Kamstrup PR. Lipoprotein(a) and ischemic heart disease--a causal association? A review. Atherosclerosis 2010; 211: 15-23. PubMed  
  5. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53. European Heart Journal  
  6. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423. Journal of the American Medical Association  
  7. Trinder M, Paruchuri K, Haidermota S, et al. Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J Am Coll Cardiol 2022. pmid:35177190 PubMed  
  • Anders Kallner, docent och fd överläkare, Karolinska universitetslaboratoriet, Karolinska universitetssjukhuset
  • Remy Waardenburg, specialist i allmänmedicin, medicinsk redaktör Medibas